Abstract
PURPOSE: Transition from intravenous epoprostenol (epo) to subcutaneous treprostinil (tre) has been reported to be feasible and safe in patients with PAH (Chest 2002; 121: 1561–5). However, the long-term outcome after transition has never been examined.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
